AHA shares proposals to lower Medicare drug prices with Congress
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program.
Related News Articles
Perspective
Stand up. Speak out. Be heard. The stakes for the future of health care are too high to do anything less. That was a key message for the approximately 1,…
Headline
It's always important to bring the issue back to the patient, said Sarah Lechner, senior vice president and chief of external affairs for Hackensack Meridian…
Headline
Three retiring members of Congress — Brad Wenstrup, R-Ohio, Larry Bucshon, R-Ind., and Dan Kildee, D-Mich. — engaged in a genial conversation that covered the…
Headline
Sen. John Thune, R-S.D., April 16 updated AHA members on progress to extend telehealth waivers, offering hope that a solution will arise in end-of-year…
Headline
As hospital leaders prepared to meet with their lawmakers on April 16 following the conclusion of the AHA's 2024 Annual Membership Meeting, Sen. Dick Durbin, D…
Headline
White House Domestic Policy Council Director Neera Tanden spoke to Annual Meeting attendees about the environment hospitals and health systems are facing and…